Adelaide Australia - Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has appointed Mr Shawn Patrick O'Brien as Chief Executive Officer (CEO) and Managing Director effective from 1 October 2022.

This follows from the previously announced retirement of Mr Scott Richards and a comprehensive search for a successor.

Mr O'Brien has more than 35 years of global pharmaceutical industry experience building successful enterprises. He is currently founding partner of Key BioPharma Partners providing advice to life science companies and capital providers. He was previously the Chairman and CEO of Genomind Inc., a personalised mental health platform company, and CEO of publicly listed Cipher Pharmaceuticals Inc., a specialty pharmaceutical company with a portfolio of commercial stage dermatology products. He has also been President and CEO of three private biotechs including AltheRx Pharmaceuticals; Profectus BioSciences and Solstice Neurosciences. Mr O'Brien held multiple senior leadership roles at AstraZeneca, one of the largest global pharmaceutical companies. At AstraZeneca he was responsible for key brands such as FASLODEX, SYMBICORT, PULMICORT and SEROQUEL which all became billion-dollar brands.

Mayne Pharma's Chair Mr Frank Condella said, 'The Board is excited to appoint someone of Shawn's calibre to lead Mayne Pharma. Shawn has been a highly effective global leader and his experience in sales and marketing, strategic planning, business development, product development and commercialisation will complement our senior leadership team. He has a proven ability to turn around organisations, lead large and diverse teams and deliver growth within both public and private companies. Shawn is an ideal choice to lead our next phase of growth and pursue Mayne Pharma's strategic agenda both organically and through strategic expansion opportunities.'

Mr Shawn Patrick O'Brien said, 'I am delighted to be part of Mayne Pharma's next phase of growth and creating value for all its stakeholders. Mayne Pharma has a compelling mix of potential nearterm opportunities for value creation including NEXTSTELLIS oral contraceptive, further expansion of the dermatology and women's health portfolio and building the International CDMO and specialty pharma business. I would like to thank the Board for their trust and confidence in allowing me to lead Mayne Pharma.'

Mr Richards will cease to be CEO and Managing Director and a member of the Board of Directors of Mayne Pharma with effect from 1 October 2022. Mr Richards will remain an employee until 30 November to help ensure a well-managed transition to the new CEO.

Contact:

Lisa Pendlebury

Tel: +61 419 548 434

Email: lisa.pendlebury@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide.

Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world.

Mayne Pharma has two facilities based in Salisbury, Australia and Greenville, NC, US with expertise in the formulation of complex oral and topical dose forms including potent compounds, modified-release products and poorly soluble compounds.

(C) 2022 Electronic News Publishing, source ENP Newswire